
Irene Lorand-Metze

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5513988/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplantation, 1998, 22, 1145-1151.	1.3	178
2	Increased risk for acute myeloid leukaemia in individuals with glutathione S -transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. European Journal of Haematology, 2001, 66, 383-388.	1.1	69
3	Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progressionâ€free survival in multiple myeloma. American Journal of Hematology, 2012, 87, 948-952.	2.0	63
4	Participation of leptin in the determination of the macrophage phenotype: an additional role in adipocyte and macrophage crosstalk. In Vitro Cellular and Developmental Biology - Animal, 2013, 49, 473-478.	0.7	60
5	Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leukemia Research, 2004, 28, 587-594.	0.4	54
6	Pancytopenia in Untreated Patients with Graves' Disease. Thyroid, 2006, 16, 403-409.	2.4	54
7	Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leukemia Research, 2007, 31, 147-155.	0.4	53
8	The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns. BMC Infectious Diseases, 2011, 11, 38.	1.3	51
9	Fractal Characteristics of May-Grünwald-Giemsa Stained Chromatin Are Independent Prognostic Factors for Survival in Multiple Myeloma. PLoS ONE, 2011, 6, e20706.	1.1	50
10	Leptin Inhibits Apoptosis in Thymus through a Janus Kinase-2-Independent, Insulin Receptor Substrate-1/Phosphatidylinositol-3 Kinase-Dependent Pathway. Endocrinology, 2006, 147, 5470-5479.	1.4	47
11	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research, 2014, 38, 1245-1251.	0.4	47
12	p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. American Journal of Hematology, 2001, 67, 84-92.	2.0	43
13	Effect of Cytokines and Chemokines on Sickle Neutrophil Adhesion to Fibronectin. Acta Haematologica, 2005, 113, 130-136.	0.7	41
14	Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface. British Journal of Pharmacology, 2001, 134, 632-638.	2.7	39
15	Causes of incidental neutropenia in adulthood. Annals of Hematology, 2006, 85, 705-709.	0.8	35
16	Adherence to Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: A Brazilian Single-Center Cohort. Acta Haematologica, 2013, 130, 16-22.	0.7	34
17	Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leukemia Research, 2008, 32, 401-405.	0.4	32
18	Bone Marrow Morphology in Patients with Neutropenia Due to Chronic Exposure to Organic Solvents (Benzene): Early Lesions. Pathology Research and Practice, 1994, 190, 151-154.	1.0	31

#	Article	IF	CITATIONS
19	Nucleolus organizer regions (AgNORs) and total tumor mass are independent prognostic parameters for treatment-free period in chronic lymphocytic leukemia. International Journal of Cancer, 2000, 89, 440-443.	2.3	30
20	Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. Cytometry, 2001, 46, 329-335.	1.8	30
21	Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 538-542.	1.3	30
22	Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leukemia Research, 2006, 30, 9-16.	0.4	29
23	Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study. Journal of Translational Medicine, 2011, 9, 23.	1.8	29
24	Acute leukemias in PiauÃ: comparison with features observed in other regions of Brazil. Brazilian Journal of Medical and Biological Research, 2003, 36, 331-337.	0.7	28
25	Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leukemia Research, 2014, 38, 251-257.	0.4	28
26	"N-rasGene Point Mutations in Brazilian Acute Myelogenous Leukemia Patients Correlate with a Poor Prognosiss― Leukemia and Lymphoma, 1997, 24, 309-317.	0.6	26
27	Bone Marrow Features in Children with HIV Infection and Peripheral Blood Cytopenias. Journal of Tropical Pediatrics, 2005, 51, 114-119.	0.7	26
28	Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia. BMC Infectious Diseases, 2010, 10, 143.	1.3	26
29	Circulating Progenitor and Mature Endothelial Cells in Deep Vein Thrombosis. International Journal of Medical Sciences, 2013, 10, 1746-1754.	1.1	26
30	Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated WithÂlmatinib. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 728-733.	0.2	26
31	Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma. Scientific Reports, 2019, 9, 16429.	1.6	26
32	Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw. Transfusion and Apheresis Science, 2013, 48, 241-246.	0.5	25
33	A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Critical Care, 2013, 17, R169.	2.5	24
34	Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 346-357.	0.7	24
35	The Fractal Dimension of Nuclear Chromatin as a Prognostic Factor in Acute Precursor B Lymphoblastic Leukemia. Analytical Cellular Pathology, 2006, 28, 55-59.	0.7	24
36	The Prognostic Relevance of Apoptosis-related Proteins in Classical Hodgkin's Lymphomas. Leukemia and Lymphoma, 2003, 44, 483-488.	0.6	23

#	Article	IF	CITATIONS
37	Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. Platelets, 2009, 20, 367-375.	1.1	23
38	Relationship between morphometric analysis of nucleolar organizer regions and cell proliferation in acute leukemias. , 1998, 32, 51-56.		22
39	Vanishing bile duct syndrome in Hodgkin's disease: case report. Sao Paulo Medical Journal, 2000, 118, 154-157.	0.4	22
40	Mutations in the p53 Gene in Acute Myeloid Leukemia Patients Correlate with Poor Prognosis. Hematology, 2002, 7, 13-19.	0.7	22
41	Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores. PLoS ONE, 2013, 8, e81048.	1.1	22
42	Histological and cytological heterogeneity of bone marrow in Philadelphia-positive chronic myelogenous leukaemia at diagnosis. British Journal of Haematology, 1987, 67, 45-49.	1.2	22
43	Expression of Epstein-Barr virus in classical Hodgkin's lymphomas in Brazilian adult patients. Haematologica, 2001, 86, 1227-8.	1.7	22
44	The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. Leukemia Research, 2008, 32, 211-213.	0.4	20
45	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, 2016, 7, 6948-6959.	0.8	20
46	Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience. Clinics, 2015, 70, 550-555.	0.6	19
47	Adult T-Cell Leukemia (ATL) with an Unusual Immunophenotype and a High Cellular Proliferation Rate. Leukemia and Lymphoma, 1996, 22, 523-526.	0.6	18
48	Tenâ€Elevenâ€Translocation 2 (<scp>TET</scp> 2) is downregulated in myelodysplastic syndromes. European Journal of Haematology, 2015, 94, 413-418.	1.1	18
49	Flow Cytometric Analysis of the Expression of Fas/Fasl in Bone Marrow CD34+Cells in Myelodysplastic Syndromes: Relation to Disease Progression. Leukemia and Lymphoma, 2004, 45, 309-313.	0.6	17
50	Lipopolysaccharide treatment reduces rat platelet aggregation independent of intracellular reactive-oxygen species generation. Platelets, 2012, 23, 195-201.	1.1	17
51	The differential diagnosis between aplastic anemia and hypocellular myelodysplasia in patients with pancytopenia. Haematologica, 1999, 84, 564-5.	1.7	17
52	Bone marrow lymphoid aggregates in myelodysplastic syndromes: incidence, immunomorphological characteristics and correlation with clinical features and survival. Leukemia Research, 2002, 26, 525-530.	0.4	16
53	Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Diagnostic Pathology, 2016, 11, 28.	0.9	16
54	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. Oncotarget, 2015, 6, 29573-29584.	0.8	16

#	Article	IF	CITATIONS
55	Early total white blood cell recovery is a predictor of low number of apheresis and good CD34+ cell yield. Transfusion Science, 2000, 23, 91-100.	0.6	15
56	Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience. Sao Paulo Medical Journal, 2000, 118, 173-178.	0.4	15
57	Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. Leukemia, 2009, 23, 144-152.	3.3	15
58	Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 2215-2221.	0.6	15
59	CHILDHOOD MYELODYSPLASTIC SYNDROMES IN A BRAZILIAN POPULATION. Pediatric Hematology and Oncology, 1999, 16, 347-353.	0.3	14
60	Frontline Therapy with Early Intensification and Autologous Stem Cell Transplantation versus Conventional Chemotherapy in Unselected High-Risk, Aggressive Non-Hodgkin's Lymphoma Patients: A Prospective Randomized GEMOH Report. Acta Haematologica, 2006, 115, 15-21.	0.7	14
61	GSTM1 and codon 72 P53 polymorphism in multiple myeloma. Annals of Hematology, 2007, 86, 815-819.	0.8	14
62	Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias. Blood Cells, Molecules, and Diseases, 2010, 44, 69-73.	0.6	14
63	Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 211-215.	0.7	14
64	Downregulation of IRS2 in myelodysplastic syndrome: A possible role in impaired hematopoietic cell differentiation. Leukemia Research, 2012, 36, 931-935.	0.4	14
65	Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors. Diagnostic Pathology, 2015, 10, 44.	0.9	14
66	Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2017, 64, e26285.	0.8	14
67	Mechanisms underlying the inhibitory effects of lipopolysaccharide on human platelet adhesion. Platelets, 2010, 21, 260-269.	1.1	13
68	Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 162-166.	0.2	13
69	Computed tomography–based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma. Nuclear Medicine Communications, 2020, 41, 377-382.	0.5	13
70	Pattern of nucleolar organizer regions in human leukemic cells. Analytical Cellular Pathology, 1993, 5, 203-12.	2.1	13
71	AgNOR clusters as a parameter of cell kinetics in chronic lymphocytic leukaemia. Journal of Clinical Pathology, 1996, 49, M357-M360.	2.1	12
72	Molecular analysis of the retinoblastoma (RB1) gene in acute myeloid leukemia patients. Leukemia Research, 1998, 22, 787-792.	0.4	11

#	Article	IF	CITATIONS
73	Changes in AgNOR configurations during the evolution and treatment of chronic lymphocytic leukemia. Hematology and Cell Therapy, 1999, 41, 205-210.	0.7	11
74	<i>Ex vivo</i> Expansion of CD56 ⁺ NK and NKTâ€like Lymphocytes from Peripheral Blood Mononuclear Cells of Patients with Ovarian Neoplasia. Scandinavian Journal of Immunology, 2011, 74, 244-252.	1.3	11
75	Viability of umbilical cord blood mononuclear cell subsets until 96 hours after collection. Transfusion, 2013, 53, 2034-2042.	0.8	11
76	The Brazilian pediatric myelodysplastic cooperative group strategies: are they relevant to improve educational approach and correct diagnosis?. Leukemia Research, 2002, 26, 637-642.	0.4	10
77	Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF. Transfusion and Apheresis Science, 2006, 34, 33-40.	0.5	10
78	An algorithm based on peripheral CD34+ cells and hemoglobin concentration provides a better optimization of apheresis than the application of a fixed CD34 threshold. Transfusion, 2008, 48, 1133-1137.	0.8	10
79	Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagulation and Fibrinolysis, 2012, 23, 75-77.	0.5	10
80	Molecular characteristics and chromatin texture features in acute promyelocytic leukemia. Diagnostic Pathology, 2012, 7, 75.	0.9	10
81	Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting. Blood, 2015, 126, 1863-1865.	0.6	10
82	Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up. Oncology Letters, 2016, 12, 485-487.	0.8	10
83	Hodgkin's disease in Brazil: a clinicopathologic study. Haematologica, 1997, 82, 127-8.	1.7	10
84	Changes of nucleolar organizer regions in granulopoietic precursors during the course of chronic myeloid leukemia. Annals of Hematology, 1995, 71, 275-279.	0.8	9
85	Lymphoblastic transformation of myelodysplastic syndrome. Sao Paulo Medical Journal, 1997, 115, 1508-1512.	0.4	9
86	Treatment of prolymphocytic leukemia with cladribine. Annals of Hematology, 1998, 76, 85-86.	0.8	9
87	Polymorphisms of glutathione S-transferase Mu 1, glutathione S-transferase theta 1 and glutathione S-transferase Pi 1 genes in Hodgkin's lymphoma susceptibility and progression. Leukemia and Lymphoma, 2009, 50, 1005-1009.	0.6	9
88	BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution. Acta Haematologica, 2015, 134, 248-254.	0.7	9
89	Normal variation of bone marrow B ell precursors according to age – reference ranges for studies in myelodysplastic syndromes in Brazil. Cytometry Part B - Clinical Cytometry, 2018, 94, 800-806.	0.7	9
90	JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia. Genetics and Molecular Biology, 2007, 30, 336-338.	0.6	9

#	Article	IF	CITATIONS
91	Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. Clinics, 2013, 68, 339-343.	0.6	9
92	Evaluation of Thrombin Generation in the Early Stages of Sepsis in Patients with Hematological Malignancies and Febrile Neutropenia,. Blood, 2011, 118, 3347-3347.	0.6	9
93	99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma. Nuclear Medicine Communications, 2020, 41, 1081-1088.	0.5	9
94	The role of bone marrow study in diagnosis and prognosis of myelodysplastic syndrome. Pathologica, 1994, 86, 47-51.	1.3	9
95	Chronic myeloid leukemia in a homosexual HIV-seropositive man. Aids, 1990, 4, 923.	1.0	8
96	Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan. Leukemia, 2000, 14, 214-215.	3.3	8
97	Multiple lymphoid nodules in bone marrow biopsy in immunocompetent patient with cytomegalovirus infection: an immunohistochemical analysis. Revista Da Sociedade Brasileira De Medicina Tropical, 2001, 34, 365-368.	0.4	8
98	Alterations in cell maturity and serum survival factors may modulate neutrophil numbers in sickle cell disease. Experimental Biology and Medicine, 2011, 236, 1239-1246.	1.1	8
99	Umbilical cord blood <scp>CD</scp> 34 ⁺ stem cells and other mononuclear cell subtypes processed up to 96Âh from collection and stored at room temperature maintain a satisfactory functionality for cell therapy. Vox Sanguinis, 2015, 108, 72-81.	0.7	8
100	Flow cytometry "Ogata score―for the diagnosis of myelodysplastic syndromes in a realâ€life setting. A Latin American experience. International Journal of Laboratory Hematology, 2019, 41, 536-541.	0.7	8
101	Goodness-of-fit of the fractal dimension as a prognostic factor. Cellular Oncology, 2009, 31, 503-4.	1.9	8
102	VARIATION OF BONE MARROW CD34+ CELL SUBSETS IN MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO TYPES. Neoplasma, 2009, 56, 435-440.	0.7	8
103	Proliferation in Non-Hodgkin'S Lymphomas and Its Prognostic Value Related to Staging Parameters. Analytical Cellular Pathology, 2004, 26, 63-71.	0.7	8
104	Phenotypic quantitative features of patients with acute myeloid leukemia. Neoplasma, 2006, 53, 155-60.	0.7	8
105	Phenotypic subtypes of acute lymphoblastic leukemia associated with different nuclear chromatin texture. , 2008, 30, 92-8.		8
106	Rapid Method for Isolation of DNA from Glass Slide Smears for PCR. Acta Haematologica, 1992, 87, 214-215.	0.7	7
107	Analysis of VÎ ³ /JÎ ² trans -rearrangements in paediatric patients undergoing chemotherapy. British Journal of Haematology, 2001, 113, 1001-1008.	1.2	7
108	Early proliferation of umbilical cord blood cells from premature neonates. Vox Sanguinis, 2007, 93, 145-153.	0.7	7

#	Article	IF	CITATIONS
109	The rare t(6;8) (q27;p11) translocation in a case of chronic myeloid neoplasm mimicking polycythemia vera. Leukemia and Lymphoma, 2008, 49, 1832-1835.	0.6	7
110	Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil. Clinics, 2015, 70, 322-325.	0.6	7
111	The impact of several phenotypic features at diagnosis on survival of patients with myelodysplastic syndromes. Neoplasma, 2010, 57, 530-536.	0.7	7
112	BONE MARROW MORPHOLOGY AT DIAGNOSIS AS A PROGNOSTIC PARAMETER IN PHILADELPHIA-POSITIVE CHRONIC MYELOGENOUS LEUKAEMIA (CML). British Journal of Haematology, 1989, 71, 163-163.	1.2	6
113	Methods for analysing AgNORs. Journal of Clinical Pathology, 1999, 52, 550a-550a.	1.0	6
114	Low expression of APAF-1XL in acute myeloid leukemia may be associated with the failure of remission induction therapy. Brazilian Journal of Medical and Biological Research, 2008, 41, 571-578.	0.7	6
115	Nucleolar organizer regions in normal hematopoiesis: relationship to cellular proliferation and maturation. , 1991, 33, 1-4.		6
116	Hemophagocytic syndrome: pitfalls in its diagnosis. Sao Paulo Medical Journal, 1997, 115, 1548-1552.	0.4	5
117	Magnetic Resonance Imaging of Femoral Marrow Cellularity in Hypocellular Haemopoietic Disorders. Clinical Radiology, 2001, 56, 107-110.	0.5	5
118	A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma. Annals of Hematology, 2003, 82, 405-409.	0.8	5
119	The influence of storage and leukocyte depletion on the antigen densities of FY1, FY2, MNS3 and MNS4 measured by flow cytometry. Transfusion and Apheresis Science, 2008, 38, 101-107.	0.5	5
120	Polymorphisms of <i>VEGF</i> , <i>GSTM1</i> and <i>GSTT1</i> genes in multiple myeloma risk. Hematological Oncology, 2012, 30, 105-107.	0.8	5
121	Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease. British Journal of Haematology, 2021, 192, 129-136.	1.2	5
122	Thalidomide + Dexamethasone as Maintenance after Single Autologous Stem Cell Transplantation Improves Progression-Free Survival (PFS) in Advanced Multiple Myeloma. A Prospective Brazilian Randomized Trial. Blood, 2008, 112, 3703-3703.	0.6	5
123	Spontaneous Apoptosis in Chronic Lymphocytic Leukemia Is Not an Independent Prognostic Factor for Stability of Disease When Compared with Combined AgNOR and TTM Scores. Analytical Cellular Pathology, 2005, 27, 199-201.	0.7	5
124	Age related decrease of AgNOR activity in acute and chronic lymphocytic leukaemias. Journal of Clinical Pathology, 1999, 52, 52-52.	2.1	4
125	Reduced expression of FLIPSHORT in bone marrow of low risk myelodysplastic syndrome. Leukemia Research, 2007, 31, 853-857.	0.4	4
126	Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma. Clinical Lymphoma and Myeloma, 2009, 9, 449-454.	1.4	4

#	Article	IF	CITATIONS
127	Monocyte phenotypic aberrancies are an unfavorable prognostic factor in patients with myelodysplastic syndromes and low IPSS-R scores. Cellular Immunology, 2016, 310, 212-213.	1.4	4
128	Metabolic Volume Measurements in Multiple Myeloma. Metabolites, 2021, 11, 875.	1.3	4
129	Acute Megakaryoblastic Leukemia: Importance of Bone Marrow Biopsy in Diagnosis. Leukemia and Lymphoma, 1991, 4, 75-79.	0.6	3
130	Association of a myelodysplastic syndrome with hairy cell leukaemia. European Journal of Haematology, 1995, 55, 341-343.	1.1	3
131	The World Health Organisation classification of myelodysplastic syndromes contains prognostically relevant information beyond the prognostic scores IPSS-R or WPSS. European Journal of Cancer, 2017, 72, 266-268.	1.3	3
132	Part 2: Myelodysplastic syndromes – classification systems. Hematology, Transfusion and Cell Therapy, 2018, 40, 262-266.	0.1	3
133	Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world. Leukemia Research, 2019, 79, 69-74.	0.4	3
134	A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes. Scientific Reports, 2020, 10, 20281.	1.6	3
135	Expression profiles of phosphatidylinositol phosphate kinase genes during normal human in vitro erythropoiesis. Genetics and Molecular Research, 2012, 11, 3861-3868.	0.3	3
136	Histiocytic necrotizing lymphadenitis in Brazil: Report of a case and review of the literature. Pathology International, 1994, 44, 548-550.	0.6	2
137	LLC: critérios diagnósticos, imunofenotipagem e diagnóstico diferencial. Revista Brasileira De Hematologia E Hemoterapia, 2005, 27, 233.	0.7	2
138	No contribution of GSTM1 and GSTT1 null genotypes to the risk of neutropenia due to benzene exposure in Southeastern Brazil. Genetics and Molecular Biology, 2009, 32, 709-711.	0.6	2
139	Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol. Advances in Hematology, 2010, 2010, 1-3.	0.6	2
140	Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2015, 37, 211-214.	0.7	2
141	Managing costs in primary immunodeficiency: minimal immunophenotyping and three national references. Apmis, 2019, 127, 228-235.	0.9	2
142	Updating recommendations of the Brazilian Group of Flow Cytometry (GBCFLUX) for diagnosis of acute leukemias using four-color flow cytometry panels. Hematology, Transfusion and Cell Therapy, 2021, 43, 499-506.	0.1	2
143	Lowering the p-value from 0.05 to 0.005 conflicts with the 3R rules – an advocacy for alternatives to hypothesis testing with the p-value approach. ALTEX: Alternatives To Animal Experimentation, 2018, 35, 516-517.	0.9	2
144	SÃndrome mielodisplásica na infância. Revista Brasileira De Hematologia E Hemoterapia, 2006, 28, .	0.7	2

#	Article	IF	CITATIONS
145	AgNOR staining in normal bone marrow cells. Journal of Clinical Pathology, 1991, 44, 526.	1.0	2
146	The Fractal Dimension Suggests Two Chromatin Configurations in Small Cell Neuroendocrine Lung Cancer and Is an Independent Unfavorable Prognostic Factor for Overall Survival. Microscopy and Microanalysis, 2022, , 1-5.	0.2	2
147	Nódulos linfóides medulares. Revista Brasileira De Hematologia E Hemoterapia, 2003, 25, 81.	0.7	1
148	Contribuição da citometria de fluxo para o diagnóstico e prognóstico das sÃndromes mielodisplásicas. Revista Brasileira De Hematologia E Hemoterapia, 2006, 28, 178.	0.7	1
149	Expressions of the VLA-4, LFA-1 and Mac-1 integrins in eosinophil migration in a case of chronic eosinophilic leukaemia. Leukemia Research, 2007, 31, 695-697.	0.4	1
150	Silver staining of nucleolar organizer regions in prostatic lesions. Histopathology, 1992, 21, 97-98.	1.6	1
151	Histological and cytological heterogeneity of bone marrow in Philadelphiaâ€positive chronic myelogenous leukaemia at diagnosis. British Journal of Haematology, 1987, 67, 45-49.	1.2	1
152	Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 442-444.	0.7	1
153	Imbalance between proliferation and in vitro apoptosis rates predicts progression in chronic lymphocytic leukemia. Cytometry Part B - Clinical Cytometry, 2016, 90, 484-485.	0.7	1
154	Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Hematology, Transfusion and Cell Therapy, 2018, 40, 255-261.	0.1	1
155	Chédiak–Higashi syndrome approached by several different microscopy imaging technologies. British Journal of Haematology, 2020, 189, 1001-1001.	1.2	1
156	Fluorescence lifetime imaging is able to recognize different hematopoietic precursors in unstained routine bone marrow films. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 641-646.	1.1	1
157	Inherited Mutation in Exon 2 of GATA-1 Is Associated with a Clinical and Laboratory Picture Similar to Familial Hypocellular Myelodysplastic Syndrome (MDS) Blood, 2004, 104, 3432-3432.	0.6	1
158	Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Blood, 2015, 126, 4031-4031.	0.6	1
159	Interaction of clinical, genetic and molecular features in chronic lymphocytic leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2006, 28, .	0.7	1
160	Chromatin Texture and Molecular Features Are Independent Prognostic Factors In AML. Blood, 2010, 116, 4850-4850.	0.6	1
161	Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses. Blood, 2012, 120, 3787-3787.	0.6	1
162	Changes of nucleolar organizer regions in granulopoietic precursors during the course of chronic myeloid leukemia. Annals of Hematology, 1995, 71, 275-279.	0.8	1

#	Article	IF	CITATIONS
163	Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia. EJHaem, 2022, 3, 698-706.	0.4	1
164	YI2 Diagnostic utility of a small four color panel for flow cytometric analysis in myelodysplastic syndromes. Leukemia Research, 2009, 33, S55.	0.4	0
165	P024 Computerized nuclear texture analysis for the characterization of atypic immature cells in MDS. Leukemia Research, 2009, 33, S71-S72.	0.4	0
166	P079 Increase in bone marrow immature nonlymphoid early precursors are indicative of a short survival in myelodysplastic syndromes. Leukemia Research, 2009, 33, S104.	0.4	0
167	SIVA, a target of p53, is downregulated in myelodysplastic syndromes. Applied Cancer Research, 2017, 37,	1.0	0
168	IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. Hematology, Transfusion and Cell Therapy, 2018, 40, 92-95.	0.1	0
169	Scoring of PD‣1 positivity: Are we analyzing enough cells?. Cancer Cytopathology, 2020, 128, 424-424.	1.4	0
170	SÃndromes mielodisplásicas, sua importância no nosso meio. Revista Brasileira De Hematologia E Hemoterapia, 2006, 28, .	0.7	0
171	Characterization of Gene Expression Profiles of Plasma Cells in Patients with Multiple Myeloma Blood, 2006, 108, 5082-5082.	0.6	0
172	High Dose Sequential (HDS) Followed by Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Salvage Treatment of Hodgkin's Disease (HD): A Brazilian Experience Blood, 2007, 110, 5103-5103.	0.6	0
173	The importance of the detection of MRD at the end of induction chemotherapy in childhood ALL. Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	0
174	A High Angiopoietin-2/Angiopoietin-1 Ratio Independently Predicts Septic Shock Development in Patients with Chemotherapy-Associated Febrile Neutropenia and Hematological Malignancies Blood, 2012, 120, 2154-2154.	0.6	0
175	ANKHD1 Interacts with the Proapoptotic Protein SIVA and Plays a Role in the Proliferation and Stathmin Activation of Acute Leukemia Cells Blood, 2012, 120, 2419-2419.	0.6	0
176	Using Antigen Expression of Leukemic Cells for a Fast Screening of Acute Promyelocytic Leukemia by Flow Cytometry. Diagnostics, 2021, 11, 1988.	1.3	0
177	The Importance of Bone Marrow Lymphocyte Subtypes As Predicting Factors for Molecular Recurrence in Patients with Chronic Myeloid Leukemia after Discontinuation of Imatinib. Blood, 2021, 138, 2564-2564.	0.6	0
178	Developing a Simple Algorithm Based on Multiparameter Flow Cytometry for Fast Screening of Acute Promyelocytic Leukemia. Blood, 2020, 136, 25-26.	0.6	0